Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis

Sodium glucose co-transporter 2 inhibitors are a new group of drugs available to treat patients with type 2 diabetes mellitus. Recently, FDA has sounded a warning of higher risk of Diabetes ketoacidosis among patients treated with this group of agents. This article reviews the available evidence to build a potential hypothesis to explain the development of this complication.